checkAd
    Startseite > Aktien > Myriad Genetics > Nachrichten
    Myriad Genetics Aktie
    23,800
     
    EUR
    +3,48 %
    +0,800 EUR
    Letzter Kurs 10.05.24 Tradegate
    23,600
     
    EUR
    860 STK
    Geldkurs 15:48:02
    23,800
     
    EUR
    840 STK
    Briefkurs 15:48:02
    ISIN: US62855J1043 · WKN: 897518 · SYM: MYD · USA

    Neueste Nachrichten

    Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA
    07.05.24 · globenewswire · Myriad Genetics
    Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business
    07.05.24 · globenewswire · Myriad Genetics
    Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024
    30.04.24 · globenewswire · Myriad Genetics
    Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor
    17.04.24 · globenewswire · Myriad Genetics
    New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel Prenatal Screen
    16.04.24 · globenewswire · Myriad Genetics
    Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing
    09.04.24 · globenewswire · Myriad Genetics
    Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
    22.03.24 · globenewswire · Myriad Genetics
    Myriad Genetics Announces Patent Granted for SneakPeek Snap Device
    20.03.24 · globenewswire · Myriad Genetics
    Fokus Aktien mit extremen Handelsvolumen am Montag, den 04.03.2024
    04.03.24 · wO Chartvergleich · Myriad Genetics
    Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the F
    27.02.24 · globenewswire · Myriad Genetics
    Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3
    27.02.24 · globenewswire · Myriad Genetics
    Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
    21.02.24 · globenewswire · Myriad Genetics